Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2015 01:35 ET | Source: DBV Technologies

DBV Technologies to Present Preclinical Data on its Viaskin(R) Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting

BAGNEUX, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
July 08, 2015 01:37 ET | Source: DBV Technologies

DBV Technologies : IND Acceptance from FDA for a proof-of-concept trial using Viaskin(r) Milk in Milk-Induced Eosinophilic Esophagitis in Children

BAGNEUX, France, July 8, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
June 30, 2015 01:39 ET | Source: DBV Technologies

DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin(R) Milk in Pediatric Cow's Milk Allergy

DSMB expressed no safety concerns and recommended that the study continue as planned Initiation of Part B expected in the second half of 2015 pending consultation with regulatory...
June 22, 2015 18:22 ET | Source: DBV Technologies

DBV Technologies Confirms Planned Initiation of Viaskin(R) Peanut Global Phase III Clinical Trial in Children Following End-of-Phase II Meeting with FDA and PIP approval by EMA

Phase III clinical trial in children expected to begin in Q4 2015 Comprehensive development plan for Viaskin Peanut announced Bagneux, France, June 22, 2015 (GLOBE NEWSWIRE) -- DBV Technologies...
June 04, 2015 01:38 ET | Source: DBV Technologies

DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin(r) Peanut for the Treatment of Peanut Allergic Children

BAGNEUX, France, June 4, 2015 (GLOBE NEWSWIRE) -- DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the...
June 02, 2015 13:36 ET | Source: DBV Technologies

DBV Technologies: Mixed General Assembly of June 23, 2015

BAGNEUX, France, June 2, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT), French biopharmaceutical company, announces that it will hold its Mixed General...
March 25, 2015 02:37 ET | Source: DBV Technologies

DBV Technologies Reports Full Year 2014 Financial Results

BAGNEUX, France, March 25, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced...
February 24, 2015 01:41 ET | Source: DBV Technologies

Viaskin(r) Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies

VIPES Phase IIb data supports Viaskin® Peanut safety and efficacy in the treatment of peanut allergy Preclinical data highlighted the unique and long-lasting therapeutic profile of...
October 23, 2014 02:35 ET | Source: DBV Technologies

Global offering of DBV Technologies ordinary shares

BAGNEUX, France, Oct. 23, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), a clinical-stage specialty biopharmaceutical company announced today that the underwriters in...
July 17, 2014 01:34 ET | Source: DBV Technologies

Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV's Viaskin(r) Peanut in Treatment of Peanut Allergy

NEW YORK and BAGNEUX, France, July 17, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of food allergies, and...